This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dalakas, M. C. Search for Related Content Social Bookmarking                   What's this?

Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies

Imperial College, London, Burlington Danes Building, Hammersmith Hospital Campus, London, m.dalakas{at}imperial.ac.uk

The inflammatory myopathies include three distinct entities: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). A T-cell-mediated cytotoxic process in PM and IBM and a complement-mediated microangiopathy in DM are the hallmarks of the underlying autoimmune processes. The most consistent therapeutic problem remains the distinction of PM from the difficult-to-treat mimics such as s-IBM, necrotizing myopathies and inflammatory dystrophies. This review provides a step-by-step approach to the treatment of inflammatory myopathies, highlights the common pitfalls and mistakes in therapy, and identifies the emerging new therapies. In uncontrolled studies, PM and DM respond to prednisone to some degree and for some period of time, while a combination with one immunosuppressive drug (azathioprine, cyclosporine, mycophenolate, methotrexate) offers additional benefit or steroid-sparing effect. In contrast, IBM is resistant to most of these therapies, most of the time. Controlled studies have shown that IVIg is effective and safe for the treatment of DM, where is used as a second, and at times first, line therapy. IVIg seems to be also effective in the majority of patients with PM based on uncontrolled series, but it offers transient help to a small number of patients with IBM especially those with dysphagia. Bona fide patients with PM and DM who become resistant to the aforementioned therapies, may respond to rituximab, tacrolimus or rarely to an tumor necrosis factor alpha inhibitor. For IBM patients, experience with alemtuzumab, a T-cell-depleting monoclonal antibody, is encouraging.

Key Words: inflammatory myopathy • polymyositis • dermatomyositis • inclusion body myositis • immunosuppressive drugs • intravenous immunoglobulin • rituximab • tacrolimus • tumor necrosis factor alpha inhibitors • alemtuzumab

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 3, 157-166 (2008)
DOI: 10.1177/1756285608097463


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?